Abstract
The labeling index (LI) of 216 cases of human brain tumors was determined by the immunohistochemical technique with monoclonal antibody to bromodeoxyuridine (BrdU). The proliferative potential of 110 cases was estimated using the intra-operative intravenous infusion of BrdU at a dose of 200 mg/sq m. In another 106 cases, thein vitro technique of incubating freshly resected tumor tissue fragments with 100 ΜM bromodeoxyuridine was used. The BrdU LI in these tumors was then correlated with the histological types and the data as determined by both thein vivo andin vitro BrdU incorporation were compared. The results indicate that althoughin vivo andin vitro techniques could possibly provide equivalent data in some histologic types, a clear statistically valid proof however is not apparent from this study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoshino T, Prados M, Wilson CB, Cho KG, Lee KS, Davis RL: Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335–341, 1989
Hoshino T, Nagashima T, Cho KG, Davis RL, Donegan J, Slusarz M, Wilson CB: Variability in the proliferative potential of human gliomas. J Neurooncol 7: 137–143, 1989
Fujimaki T, Matsutani M, Nakamura O, Asai A, Funada A, Koike M, Segawa H, Aritake K, Fukushima T, Houjo Set al.: Correlation between bromodeoxyuridine labeling indices and patient prognosis in cerebral astrocytic tumors of adults. Cancer 67: 1629–1634, 1991
Germano IM, Ito M, Cho KG, Hoshino T, Davis RL, Wilson CB: Correlation of histopathological features and proliferative potential of gliomas. J Neurosurg 70: 701–706, 1989
Nishizaki T, Orita T, Saiki M, Furutani Y, Aoki H: Cell kinetics studies of human brain tumors byin vitro labeling using anti-BUdR monoclonal antibody. J Neurosurg 69: 371–374, 1988
Nishizaki T, Orita T, Furutani Y, Ikeyama Y, Aoki H, Sasaki K: Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors. J Neurosurg 70: 379–384, 1989
Morimura T, Kitz K, Budka H:In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a newin vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67. Acta Neuropathol 77: 276–282, 1989
Nishizaki T, Orita T, Kajiwara K, Ikeda N, Ohshita N, Nakayama H, Furutani Y, Ikeyama Y, Akimura T, Kamiryo Tet al.: Correlation ofin vitro bromodeoxyuridine labeling index and DNA aneuploidy with survival or recurrence in brain-tumor patients. J Neurosurg 73: 396–400, 1990
Morimura T, Kitz K, Stein H, Budka H: Determination of proliferative activities in human brain tumor specimens. A comparison of three methods. J Neurooncology 10: 1–11, 1991
Detta A, Hitchcock E: Rapid estimation of the proliferative index of brain tumors. J Neurooncol 8: 245–253, 1990
Meyer JS, Nauert J, Koehm S, Hughes J: Cell kinetics of human tumors byin vitro bromodeoxyuridine labeling. J Histochem Cytochem 37: 1449–1454, 1989
Kharbanda K, Karak AK, Sarkar C, Dinda A, Mathur M, Roy S: Prediction of biologic aggressiveness in human meningiomas: A cell kinetic study using bromodeoxyuridine in cells of primary expiant culture. J Natl Can Inst 84: 194–195, 1992
Kajiwara K, Nishizaki T, Orita T, Nakayama H, Aoki H, Ito H: Silver colloid staining technique for analysis of glioma malignancy. J Neurosurg 73: 113–117, 1990
Orita T, Kajiwara K, Nishizaki T, Ikeda N, Kamiryo T, Aoki H: Nucleolar organizer regions in meningiomas. Neurosurgery 26: 43–46, 1990
Zulch KJ: Histological typing of tumors of central nervous system. International Histologic classification of tumors, No21, Geneva: WHO; 1979, pp 19–62
Kepes JJ: Review of the WHO's new proposed classification of brain tumors. In: Proceedings of the XIth International Congress of Neuropathology, Kyoto, September 2–8, 1990; pp 87–102
Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique. A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580, 1981
Bagshaw MA, Doggett RLS, Smith KC, Kaplan HS, Nelsen TS: Intra-arterial 5-bromodeoxyuridine and X-ray therapy. AJR 99: 886–894, 1967
Hoshino T, Sano K: Radiosensitization of malignant brain tumors with bromouridine (thymidine analoque). Acta Radiol (Ther) 8: 15–26, 1969
Goz B: The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev 29: 249–272, 1977
Heartlein MW, O'Neill JP, Pal BC, Preston RJ: The induction of specific locus mutations and sister-chromatid exchanges by 5-bromo and 5-chloro-deoxyuridine. Mutat Res 92: 411–416, 1982
San Sebastian JR, O'Neill JP, Hsie AW: Induction of chromosome aberrations, sister chromatid exchanges and specific locus mutations in Chinese hamster ovary cells by 5-bromodeoxyuridine. Cytogenet Cell Genet 28: 47–54, 1980
Steel GG, Bensted JPM:In vitro studies of cell proliferation in tumors-I, Critical appraisal of methods and theoretical considerations. Eur J Cancer 1: 275–279, 1965
Johnson HA: Some problems associated with the histological study of cell proliferation kinetics. Cytologia 26: 32–41, 1961
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kharbanda, K., Dinda, A.K., Sarkar, C. et al. A correlative study ofin vivo andin vitro labeling index using bromodeoxyuridine in human brain tumors. J Neuro-Oncol 23, 185–190 (1995). https://doi.org/10.1007/BF01059949
Issue Date:
DOI: https://doi.org/10.1007/BF01059949